- The FDA has imposed a partial clinical hold on Geron's (GERN) Imetelstat treatment in a trial for myelofibrosis, as the drug may be toxic to the liver.
- Geron can't enroll new patients into the study, although patients who are benefiting from the treatment will be able to continue receiving it.
- The FDA's action adds to the full holds it placed on Phase II trials for essential thrombocythemia and multiple myeloma.
- Geron's shares are flat after being higher earlier. (PR)
at Zacks.com (Nov 17, 2014)